🇺🇸 FDA
Patent

US 11124839

Methods of treating cancer patients with farnesyltransferase inhibitors

granted A61KA61K31/00A61K31/4709

Quick answer

US patent 11124839 (Methods of treating cancer patients with farnesyltransferase inhibitors) held by Kura Oncology, Inc. expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kura Oncology, Inc.
Grant date
Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/00, A61K31/4709, A61P, A61P35/00